ArticleScientific reports2026
Thapsigargin enhanced chemotherapeutic sensitivity of irinotecan in the inflammation-induced colorectal cancer model in mice.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Iron and Other Metal Ions in Human Health and Disease.MedComm · 2026Review
- Epigallocatechin-3-Gallate, the green tea polyphenol suppresses expression of CD31 and VEGFR2 and enhances the chemotherapeutic potential of irinotecan in AOM/DSS model of colorectal cancer in mice.Journal of the Egyptian National Cancer Institute · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study used an in-vivo inflammation-induced colorectal cancer (CRC) model to evaluate the additive effect of thapsigargin (TG) with the standard chemotherapy drug irinotecan (IRN). CRC was induced by AOM/DSS, and after 10th weeks, animals were treated with five weekly cycles of either IRN or TG or a combination of both drugs. All the animals were sacrificed after the 16th week, and the data were analysed. Coadministration of both IRN and TG substantially reduced both tumor numbers and occurrence of aberrant crypt foci (ACF) in the colon tissues as compared to only IRN/TG-treated animal groups. Further analyses revealed that IRN and TG together alleviated ultrastructural abnormalities of the colon with a recovered overall histoarchitecture, enhanced ER stress and mitochondrial dysfunction, reduction of PCNA positive cells indicating low rate of cellular proliferation, increased DNA fragmentation and apoptosis supported by higher intensity of γH2AX and cleaved caspase-3 immunohistochemistry. Gene expression analyses of key oncogenic biomarkers also suggest that the addition of TG with IRN is more effective in inhibiting carcinogenic transformation in the colon of AOM/DSS-treated mice. This study provides direct evidence of the superior therapeutic potential of a combination of both drugs compared to conventional monotherapy in the management of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.